Nexstim: Our Comment On the Rights Issue

Research Note

2021-04-08

08:59

Redeye adjusts its fair value range following Nexstim’s completed rights issue. The company has secured funding for its ongoing operations and further pilot studies on an accelerated treatment for its depression therapy (NBT System).

FT

Fredrik Thor

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.